Nrf2 and PGC-1α signaling in temozolomide resistance in glioblastoma under hypoxia
Pinpat Tripatara, Tasanee Onkoksoong, Sunisa Prasopporn, Sith Sathornsumetee, Siwanon Jirawatnotai, Uraiwan Panich · 2026
Read Nrf2 and PGC-1α signaling in temozolomide resistance in glioblastoma under hypoxia by Pinpat Tripatara, Tasanee Onkoksoong, Sunisa Prasopporn, Sith Sathornsumetee, Siwanon Jirawatnotai, Uraiwan Panich (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13636387.txt.
Description
Pinpat Tripatara and co-authors probed why low oxygen helps a brain tumor resist its main chemotherapy drug, in a 2026 study. Glioblastoma tumors grow hypoxic pockets where the drug temozolomide works poorly. The team grew a glioblastoma cell line in normal and low oxygen, and tested the drug alone and paired with brusatol, a compound that suppresses the Nrf2 stress-defense pathway.
Low oxygen sharply raised the drug dose needed to kill half the cells, alongside higher levels of a hypoxia marker and more Nrf2 gathering in the nucleus. The pairing was synergistic in normal oxygen but not, by the formal measure, in low oxygen, though brusatol still sensitized cells there by direct counts. Hypoxia also switched on a battery of antioxidant and growth genes and moved a mitochondrial regulator, PGC-1 alpha. The authors map this defense network as a target list for overcoming resistance.
Catalog record
| CREATOR | Pinpat Tripatara, Tasanee Onkoksoong, Sunisa Prasopporn, Sith Sathornsumetee, Siwanon Jirawatnotai, Uraiwan Panich |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |